Bayer Aims For Global OTC Lead With Bolt-On Acquisition Plans
This article was originally published in The Tan Sheet
Executive Summary
Chairman Marijn Dekkers says the German company believes strong organic growth and consumer health pick-ups will help Bayer become the world leader in OTCs.
You may also be interested in...
Reckitt Deals Feed OTC Domination Plan
Reckitt Benckiser CEO Rakesh Kapoor plays up the firm’s potential to dominate the fragmented global consumer health product market and says Reckitt is better positioned than big pharma firms to manage OTC businesses. Reckitt continued its emerging markets focus with OTC deals in Latin America and China.
Sales & Earnings In Brief
Sanofi now world’s No. 3 OTC player; Glaxo weighs Lucozade energy drink divestment; NBTY wraps Balance Bar integration; Vicks launches in Europe boost Teva OTC business; flu trend breeds cautious optimism for Prestige Brands; USANA and Nu Skin face tough times for multilevel marketers.
Reckitt’s Schiff Buy Reflects Nutritional Industry “On Fire”
Reckitt Benckiser went high with its $1.4 billion bid for Schiff Nutrition, though the acquisition’s impressive multiples are not entirely out of line with earlier deals in the nutrition space. Analyst Damian Witkowski notes that Airborne, MegaRed and other Schiff brands already are primed for organic growth.